PATENT LICENSE AGREEMENT n° C-00061906Patent License Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
IP is owner of patents and patent applications relating to a method of homologous recombination. IP has already granted exploitation rights for these patents and patent application to third parties for specific applications and now wishes to share this technology with a new industrial partner.
STOCKHOLDERS AGREEMENTStockholders Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances) • Delaware
THIS STOCKHOLDERS AGREEMENT (as it may be amended from time to time in accordance with the terms hereof, this “Agreement”), dated as of July 25, 2017, is made by and among Calyxt, Inc., a Delaware corporation (the “Company”), Cellectis S.A., a French société anonyme (“Cellectis”) and the Persons listed on Schedule A hereto (each, a “Non-Cellectis Holder” and collectively, the “Non-Cellectis Holders”).
LICENSE AGREEMENTLicense Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
This LICENSE AGREEMENT (this “Agreement”), dated as of July 25, 2017 (the “Effective Date”), is entered into by and between Cellectis S.A., a corporation existing and registered under the laws of France, located at 8 rue de la Croix Jarry, 75013 Paris, France (“Cellectis”), and Calyxt, Inc., a corporation existing and registered under the laws of Delaware, located at 600 County Road D West, Suite 8, New Brighton, MN 55112, USA (“Calyxt”) (each a “Party” and collectively, the “Parties”).
SEPARATION AGREEMENTSeparation Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances) • New York
THIS SEPARATION AGREEMENT, dated as of July 25, 2017, is by and between CELLECTIS S.A., a French société anonyme (“Cellectis”) and CALYXT, INC., a Delaware corporation (the “Company” and each of Cellectis and the Company, a “Party” and, together, the “Parties”). Capitalized terms used herein shall have the respective meanings assigned to them in Article 1 hereof.
MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
This Agreement is made by and between CELLECTIS SA, a French Société Anonyme, located at 8, rue de la Croix Jarry, 75013 Paris, France, (hereinafter “CLS”); CELLECTIS, INC., a Delaware corporation, located at 430 East 29th Street, New York, New York, 10016, USA (hereinafter “CLI”); and CALYXT, INC., a Delaware corporation, located at 600 County Road D West, Suite 8, New Brighton, MN 55112, USA, (hereinafter “CLX”). CLS, CLI, and CLX are thereafter named individually, a “Party” and together the “Parties”.
FIRST AMENDMENT TO THE MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE MANAGEMENT SERVICES AGREEMENT (the “Amendment”) is entered into and made effective as of July 25, 2017 by and among Cellectis S.A. (“CLS”), Cellectis, Inc. (“CLI”) and Calyxt, Inc. (“CLX”), each a Party and together the Parties.
CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A. LICENSE AGREEMENTLicense Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances) • New York
This License Agreement (the “Agreement”) is entered into as of March 8, 2019 (the “Effective Date”), by and among Allogene Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 210 East Grand Avenue, South San Francisco, California, 94080 (“Allogene”) and Cellectis SA, a corporation organized and existing under the laws of France and having a place of business at 8 rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Allogene and Cellectis may each be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT N0 1 TO THE PATENT LICENSE AGREEMENT n° C-00061905Patent License Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
Public limited company with capital with a capital of 122,363.47 euros, with its registered office at at 28, rue du Docteur Roux, 75724 Paris cedex 15, represented by Mr. André Choulika, acting in the capacity of CEO
CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.License, Development and Commercialization Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
This License, Development and Commercialization Agreement shall become effective as of the 6th day of March, 2019 (the “Effective Date”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and Institut de Recherches Internationales Servier, a corporation incorporated under the laws of France having its principal place of business at 50 rue Carnot, 92 150 Suresnes, France (“IRIS”) (LLS and IRIS being together referred to as “Servier”), and Cellectis SA, a company incorporated under the laws of France having a principal place of business at 8, rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Cellectis and Servier are individually referred to herein as a “Party” and collectively, as the “Parties.”
AMENDMENT NO. 1 TO THE PATENT LICENSE AGREEMENT NO. C-00061901Patent License Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
L’Institut Pasteur, a public interest foundation, 25, rue du Docteur Roux, 75015 Paris, represented by Mr. Jean Castex, adjunct General Manager for administration and finance, and by Mr. Christian POLICARD, Director of Business Development and Industrial Partnerships.
AMENDMENT NO. 2 TO THE PATENT LICENSE AGREEMENT NO. C-00061906Patent License Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
L’Institut Pasteur, a public interest foundation, 25, rue du Docteur Roux, 75015 Paris, represented by Mr. Jean Castex, adjunct General Manager for administration and finance, and by Mr. Christian POLICARD, Director of Business Development and Industrial Partnerships.
PATENT & TECHNOLOGY LICENSE AGREEMENT AGT. NO. A2014-1834Patent & Technology License Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances) • Ohio
This Patent & Technology License Agreement (“PTLA”) is by and between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”).
AMENDMENT NO. 1 TO THE PATENT LICENSE AGREEMENT NO. C-00061906Patent License Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
On June 19, 2000, the Parties signed licensing agreement no. C-00061906 (hereafter the “AGREEMENT”), by which the LICENSOR grants the LICENSEE exploitation rights under the above mentioned patents and patent applications.
SCHEDULE A AMENDMENT NO. 4 TO PATENT LICENSING AGREEMENT NO. C-00061906Patent Licensing Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
On June 19, 2000, the Parties signed the license agreement no. C-00061906 (hereafter the “AGREEMENT”), by which the LICENSOR grants the LICENSEE exploitation rights to the above mentioned patents and patent applications.
AMENDMENT NO. 2 TO THE PATENT LICENSE AGREEMENT NO. C-00061901Patent License Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
L’Institut Pasteur, a public interest foundation, 25, rue du Docteur Roux, 75015 Paris, represented by Mr. Jean Castex, adjunct General Manager for administration and finance, and by Mr. Christian POLICARD, Director of Business Development and Industrial Partnerships.
AMENDMENT NO. 3 TO THE PATENT LICENSE AGREEMENT NO. C-00061906Patent License Agreement • March 12th, 2019 • Cellectis S.A. • Biological products, (no disgnostic substances)
L’Institut Pasteur, a public interest foundation, 25, rue du Docteur Roux, 75015 Paris, represented by Mr. Jean Castex, adjunct General Manager for administration and finance,
